Molecular Targets for Treatment of Breast Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Woo-Chan | - |
dc.contributor.author | Kim, Lee Su | - |
dc.contributor.author | Kim, Tae Hyun | - |
dc.contributor.author | Park, Byeong-Woo | - |
dc.contributor.author | Park, Ho Yong | - |
dc.contributor.author | Song, Byung Joo | - |
dc.contributor.author | Lee, Jae Bok | - |
dc.contributor.author | Jeon, Chang Wan | - |
dc.contributor.author | Choi, Un-Jong | - |
dc.date.available | 2020-11-10T12:53:24Z | - |
dc.date.issued | 2009-12 | - |
dc.identifier.issn | 1738-6756 | - |
dc.identifier.issn | 2092-9900 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/31171 | - |
dc.description.abstract | Advances in molecular biology have made it possible to understand the tumor biology of breast cancer at the molecular level and have revealed molecular targets for the therapy of breast cancer. Nowadays, targeting agents are used as mono-therapy or as combined therapy with other anticancer drugs for the treatment of breast cancer. Much more efforts is also being made in the development of better therapeutic agents targeting molecules having an important role in tumor biology. In this article, promising molecules for targeted therapy are reviewed for their roles in the pathophysiology and the treatment of breast cancer. We also introduce and summarize new preclinical agents, developed or on developing, with preliminary results from clinical trials. Given the progress currently being made, targeted therapy could become a main strategy for the treatment of breast cancer in the near future. | - |
dc.format.extent | 6 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | KOREAN BREAST CANCER SOC | - |
dc.title | Molecular Targets for Treatment of Breast Cancer | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4048/jbc.2009.12.4.229 | - |
dc.identifier.scopusid | 2-s2.0-74849116372 | - |
dc.identifier.wosid | 000273621900001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF BREAST CANCER, v.12, no.4, pp 229 - 234 | - |
dc.citation.title | JOURNAL OF BREAST CANCER | - |
dc.citation.volume | 12 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 229 | - |
dc.citation.endPage | 234 | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART001409731 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kciCandi | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITOR | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | POLY(ADP-RIBOSE) POLYMERASE | - |
dc.subject.keywordPlus | PLUS CAPECITABINE | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordAuthor | Breast neoplasms | - |
dc.subject.keywordAuthor | Therapy | - |
dc.subject.keywordAuthor | Targeting agent | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.